Takaisin

Effect of phentermine topiramate on weight loss in adults with overweight or obesity

Näytönastekatsaukset
Yasmina Silén and Bianca Arrhenius
17.11.2026

Level of evidence: B

In adults with overweight (BMI ≥27 kg/m²) and obesity-related comorbidities or severe obesity (BMI >35 kg/m2), daily oral phentermine-topiramate 7.5/46 mg or 15/92 mg results in clinically meaningful, dose-dependent weight loss compared to placebo, with an average reduction in total body weight of approximately 7-9% over follow-up periods ranging from 1 to 2 years.

The quality of evidence is downgraded due to study limitations (selection bias and attrition bias).

Table 1. Description of the included studies
Reference Study type Population Intervention and comparison Outcomes Risk of bias «Additional comments for included studies...»2
RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis
«Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 Gadde et al. 2011
CONQUER-study
Multicenter RCT Adults aged 18-70 years with BMI 27-45 kg/m2 and two or more obesity-related comorbidities (hypertension, dyslipidemia, diabetes or prediabetes, abdominal obesity). Three groups:
Placebo, phentermine+topiramate 7.5/46 mg, phentermine+topiramate 15/92 mg. Oral administration. All groups received lifestyle counseling
Percentage change in bodyweight and proportion of patients achieving at least 5% weight loss at 56 weeks Low
«Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 Garvey et al. 2011
SEQUEL-study
Multicenter RCT
Follow-up study to Gadde et al.
Adults with BMI 27–45 kg/m² and ≥2 obesity-related comorbidities (hypertension, dyslipidemia, diabetes, abdominal obesity). Three groups: Phentermine/topiramate 7.5/46 mg, 15/92 mg or placebo. Oral administration. All groups received lifestyle counseling. Percentage change in bodyweight and proportion of patients achieving ≥5%, ≥10%, ≥15% weight loss at 108 weeks Moderate
«Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Allison et al. 2011
EQUIP-study
Multicenter RCT Adults 18–70 years with severe obesity BMI ≥35 kg/m². Three groups: Phentermine/topiramate 3.75/23 mg, 15/92 mg or placebo. Oral administration. All groups received lifestyle counseling including a 500 kcal/day energy deficit. Percentage change in bodyweight and proportion of patients achieving ≥5%, ≥10%, ≥15% weight loss at 56 weeks Moderate
Table 2. Additional comments for included studies
Reference Comments
«Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 CONQUER-study. High number of dropouts (31%), but results were similar in ITT and sensitivity analyses across groups. Weight loss results were similar regardless of comorbidity. Industry funded.
«Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 SEQUEL was a 52-week double-blind, placebo-controlled extension of the CONQUER trial, conducted at 36 of 93 U.S. sites chosen for high participant retention and enrollment. Participants remained in their original randomized groups (placebo or phentermine/topiramate 7.5/46 mg or 15/92 mg), for a total treatment duration of 108 weeks. Randomization was stratified by sex and type 2 diabetes status. Of the 866 CONQUER completers at eligible sites, 676 (78%) enrolled in SEQUEL (69% placebo, 79% 7.5/46 mg, 86% 15/92 mg), and 84% completed it. The modified ITT population included participants with at least one dose and one post-baseline weight measurement. The effect size may be somewhat overestimated, as participants who continued were possibly more motivated and adherent. Industry funded.
«Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Double-blinded, placebo-controlled, multicenter RCT. High dropout rate (placebo 47.1%, low dose 39.0%, high dose 33.6%) raising attrition bias concern. Primary ITT-analysis included all randomized patients who received at least one dose of drug/placebo and had at least one post-randomization weight measurement. Of the participants 83% were females. Industry funded.

Results

Table 3. Weight loss
Reference Number of studies and number of patients (I/C) Follow-up time Weight loss in kg:s mean, (%) I Weight loss in kg:s mean, (%) C Estimated difference:
(95% CI)
Level of evidence: moderate. The quality of evidence is downgraded due to study limitations (selection bias and attrition bias).
I= intervention; C=comparison; CI=confidence interval
«Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 Gadde et al. 2011 I: 7.5/46mg N=488
15/92mg
N=981
C: placebo N=979
56 weeks 7.5/46mg:
-8.1 kg (-7.8%)
15/92mg:
-10.2 kg (-9.8%)
Placebo:
-1.4kg (-1.2%)
7.5/46 mg:
-6.6% (-7.4 to -5.8)
15/92mg:
-8.6% (-9.3 to -8.0)
«Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 Garvey et al. 2011 I: 7.5/46 mg N=153,
15/92mg
N=295
C: placebo N=227
108 weeks 7.5/46 mg:
-9.6 kg (–9.3%)
15/92 mg:
-10.9 kg (–10.5%)
Placebo:
-2.1 kg (-1.8%)
7.5/46 mg:
–7.5 %
15/92 mg:
–8.7 %
«Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Allison et al. 2011 I: 15/92mg N=498,
C: placebo N=498
56 weeks 15/92 mg:
-10.9% (-10.2-11.7%)
Placebo:
-1.6% (-0.8-2.3%)
15/92 mg:
-9.3 %
Table 4. Weight loss, 5, 10 and 15%
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Odds ratio (95% CI)
Level of evidence: moderate. The quality of evidence is downgraded due to study limitations (selection bias and attrition bias).
I= intervention; C=comparison; CI=confidence interval
«Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 Gadde et al. 2011 I: 7.5/46mg N=488
15/92mg N=981
C: placebo N=979
56 weeks 5% weight loss:
7.5/46 mg: 303 (62%)
15/92mg: 687 (70%)
5% weight loss:
204 (21%)
6.3 (4.9-8.0)
9.0 (7.3-11.1)
10% weight loss:
7.5/46 mg: 182 (37%)
15/92mg: 467 (48%)
10% weight loss:
72 (7%)
7.6 (5.6-10.2)
11.7 (8.9-15.4)
«Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 Garvey et al. 2011 I: 7.5/46 mg N=153,
15/92mg N=295
C: placebo 227
108 weeks 5% weight loss:
7.5/46 mg: 75.2%
15/92 mg: 79.3%
5% weight loss:
30.0%
-
10% weight loss:
7.5/46 mg: 50.3%
15/92 mg: 53.9 %
10% weight loss: 11.5%
15% weight loss:
7.5/46 mg:
24.2%
15/92 mg: 31.9%
15% weight loss: 6.6%
«Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Allison et al. 2011 I: 15/92mg N=498,
C: placebo N=498
56 weeks 5% weight loss:
15/92mg: 332 (66.7%)
5% weight loss:
83 (17.3%)
-
10% weight loss:
15/92mg: 235 (47.2%)
10% weight loss:
37 (7.4%)
15% weight loss:
15/92mg: 161 (32.3% )
15% weight loss
17 (3.4%)

References

  1. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52 «PMID: 21481449»PubMed
  2. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308 «PMID: 22158731»PubMed
  3. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20(2):330-42 «PMID: 22051941»PubMed